Boceprevir

摘要: Boceprevir (Victrelis®) is an inhibitor of the hepatitis C virus (HCV) non-structural protein NS3-4A serine protease and used in combination with pegylated interferon (peginterferon)-alpha ribavirin treatment adults chronic HCV (chronic C) genotype 1 infection. Of various genotypes HCV, one least responsive to ribavirin-based therapy, thus most need novel treatments. This article reviews available pharmacological properties boceprevir its clinical efficacy tolerability infection adult patients who are either treatment-naive or have failed previous standard therapy. Boceprevir, when co-administered peginterferon-alpha were had previously not fully responded relapsed following treatment, was associated a significantly higher sustained virological response rate (defined as proportion undetectable plasma RNA level at week 24 follow-up period [week 72 overall]) [primary endpoint] than peginterferon-alpha-2b alone, regardless administration regimen, phase III SPRINT-2 (treatment-naive patients) RESPOND-2 (previously treated trials. There no significant difference between full-duration (44 weeks) response-guided (24 32 weeks followed by plus alone) regimen recipients regard rate. All received initial 4-week lead-in before comparative began. Overall, generally well tolerated administered concomitantly The common adverse events any group flu-like symptoms, which typically reported receiving peginterferon-ribavirin addition increased risk anaemia neutropenia. In conclusion, effective for drug rates these patients, whom alone may be successful. Thus, valuable new option use